Screener
Spyre Therapeutics, Inc. SYRE Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Series A non-voting convertible preferred stock, $0.0001 par value; 1,086,341 shares authorized as of March 31, 2026 and December 31, 2025; 346,045 shares issued and outstanding as of March 31, 2026 and December 31, 2025. | 146,425 | 146,425 |
| Series B non-voting convertible preferred stock, $0.0001 par value; 271,625 shares authorized and 16,667 shares issued and outstanding as of March 31, 2026 and December 31, 2025. | 9,395 | 9,395 |
| Preferred stock, $0.0001 par value; 8,642,034 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025. | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 78,839,858 shares and 78,189,811 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | 15 | 15 |
| Additional paid-in capital | 1,712,383 | 1,686,167 |
| Accumulated other comprehensive (loss) income | (767) | 869 |
| Accumulated deficit | (1,196,640) | (1,127,635) |
| TOTAL STOCKHOLDERS’ EQUITY | 670,811 | 715,236 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s common stock?
- Spyre Therapeutics, Inc. (SYRE) reported common stock of 400M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s common stock changed year-over-year?
- Spyre Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from 400M to 400M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s common stock?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s common stock has grown at a 856.4% compound annual growth rate (CAGR), from 5K to 400M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Spyre Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude